A Medical Device Daily

IJJ Corp. said it has acquired Rapid Diagnostic Testing (both Capital Heights, Maryland), a company that provides medical testing equipment and solutions for the detection of illnesses such as HIV/AIDS, Malaria, Tuberculosis, E. Coli and other infectious diseases. The Rapid Diagnostics Testing solution is offered to private industry, local, state, federal and foreign governments, as well as non-profit organizations, the company noted.

"We are excited about the acquisition of Rapid Diagnostics Testing and are working closely with the company to close sales in the pipeline," said Clifford Pope, CEO of IJJ.

Rapid Diagnostics Testing specializes in the global distribution and reselling of rapid medical diagnostic detection and treatment products for a large number of infectious diseases. Test results can be obtained within three to 30 minutes, according to the company. Rapid Diagnostics Testing says it provides high-quality point-of-care medical rapid diagnostic tests, laboratory diagnostic equipment and pharmaceutical products in conjunction with a vast array of tests for the detection of drugs of abuse.

In other dealmaking activity:

• The law offices of Howard G. Smith reported that it is investigating potential claims against the board of Aspect Medical Systems (Norwood, Massachusetts) related to the company's agreement to be acquired by Covidien (Dublin, Ireland and Mansfield, Massachusetts) in a cash transaction valued at roughly $210 million, net of cash and short-term investments acquired (Medical Device Daily, Sept. 29, 2009).

The investigation concerns possible breaches of fiduciary duty and other violations of state law related to approval of the transaction by the Aspect Medical board of directors.

• The boards of Consort Medical (Hemel Hempstead, UK) and The Medical House (Sheffield, UK) said they have reached agreement on the terms of a recommended cash offer to be made by Consort Medical to acquire the entire issued and to be issued share capital of The Medical House.

The Medical House shareholders will receive 27.5 pence in cash for each share held. The offer values the entire issued share capital of The Medical House at about 16.5 million.

The offer represents a premium of about 93% to the closing price of 14.25 pence per The Medical House share on Aug. 11, the last dealing day prior to the announcement by The Medical House that it had received a preliminary approach.

Consort said it views the acquisition of The Medical House as "an attractive opportunity to enhance Consort Medical's existing position as a leading global supplier of drug delivery device and airway management product technologies."